Robotic transversus abdominis release (TAR) for ventral hernia repairs is associated with low surgical site occurrence rates and length of stay despite increasing modifiable comorbidities
Hernia · 2024
DOI: 10.1007/s10029-024-03044-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hernia, 2024. Verfasst von A C Skoczek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Edward Via College of Osteopathic Medicine - Auburn, 910 S Donahue Dr., Auburn, AL, 36830, USA. askoczek@auburn.vcom.edu. Hauptthemen laut MEDLINE: Hernia, Ventral, Robotic Surgical Procedures, Length of Stay, Herniorrhaphy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Modifiable comorbidities (MCMs) have previously been shown to complicate postoperative wound healing occasionally leading to surgeon hesitancy to repair ventral hernias prior to preoperative optimization of comorbidities. This study describes the effects of MCMs on surgical site occurrences (SSOs) and hospital length of stay (LOS) following robotic transversus abdominis release (TAR) with poly-4-hydroxybutyrate (P4HB) resorbable biosynthetic mesh retromuscular sublay for ventral hernia repair in patients who had not undergone preoperative optimization.
Methods
A single-surgeon retrospective review was performed for patients who underwent the robotic TAR procedure with P4HB mesh between January 2015 and May 2022. Patients were stratified by the amount of MCMs present: 0, 1, or 2 + . MCMs included obesity, diabetes, and current tobacco use. Patient data was analyzed for the first 60 days following their operation. Primary outcomes included 60-day SSO rates and hospital LOS.
Results
Three hundred and thirty-four subjects met the inclusion criteria for SSO and prolonged LOS analysis. 16.8% had no MCM, 56.1% had 1 MCM, and 27% had 2 + MCMs. No significant difference in SSO was seen between the 3 groups; however, having 2 + MCMs was significantly associated with increased odds of SSO (odds ratio 3.25, P = .019). When the groups were broken down, only having a history of diabetes plus obesity was associated with significantly increased odds of SSO (odds ratio 3.54, P = .02). No group showed significantly increased odds of prolonged LOS.
Conclusion
2 + MCMs significantly increase the odds of SSO, specifically in patients who have a history of diabetes and obesity. However, the presence of any number of MCMs was not associated with increased odds of prolonged LOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Edward Via College of Osteopathic Medicine - Auburn, 910 S Donahue Dr., Auburn, AL, 36830, USA. askoczek@auburn.vcom.edu.
- Edward Via College of Osteopathic Medicine - Carolinas, Spartanburg, SC, USA.
- Lincoln Memorial University DeBusk College of Osteopathic Medicine - Knoxville, Knoxville, TN, USA.
- Crestwood Medical Center, Huntsville, AL, USA.
ORCID-Profile: A C Skoczek, P W Ruane, A B Holland, J K Hamilton
Zitieren
APA
Skoczek, A. C., Ruane, P. W., Holland, A. B., Hamilton, J. K., & Fernandez, D. L. (2024). Robotic transversus abdominis release (TAR) for ventral hernia repairs is associated with low surgical site occurrence rates and length of stay despite increasing modifiable comorbidities. Hernia. https://doi.org/10.1007/s10029-024-03044-6
Vancouver
Skoczek AC, Ruane PW, Holland AB, Hamilton JK, Fernandez DL. Robotic transversus abdominis release (TAR) for ventral hernia repairs is associated with low surgical site occurrence rates and length of stay despite increasing modifiable comorbidities. Hernia. 2024. doi:10.1007/s10029-024-03044-6
BibTeX
@article{Skoczek2024,
author = {Skoczek, A C and Ruane, P W and Holland, A B and Hamilton, J K and Fernandez, D L},
title = {Robotic transversus abdominis release (TAR) for ventral hernia repairs is associated with low surgical site occurrence rates and length of stay despite increasing modifiable comorbidities},
journal = {Hernia},
year = {2024},
doi = {10.1007/s10029-024-03044-6}
}
EUVIMED